Altimmune Inc (ALT)
4.55
-0.33%
Altimmune Inc (ALT) is currently trading at $4.55. This represents a loss of 0.33% from the previous session. With a market capitalization of $0.51B, ALT is a key component of the Health Care sector. Investors looking to trade ALT should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Get 15 Free Stocks on Moomoo →
T&Cs Apply. Trade ALT commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Altimmune Inc (ALT) shows a bearish trend. Analysts are watching the 4.61 level closely.
Fundamentals
Mkt Cap0.51B
P/E Ratio0.0000
Volume1,435,487
60-Day Technical Chart
Advanced Charting
Need more indicators for ALT? Use the world's #1 platform.
Open ALT on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $5
| Metric |
ALT -0.33% |
UWMC -8.65% |
OPEN -3.62% |
AUR +0.72% |
|---|---|---|---|---|
| Price | $4.55 | $4.17 | $4.97 | $4.89 |
| Mkt Cap | $0.51B | $6.68B | $4.75B | $9.49B |
| - | View → | View → | View → |
Latest Headlines
Does Altimmune (ALT) Have the Potential to Rally 229.28% as Wall Street Analysts Expect?
Yahoo Finance • Dec 11, 2025
Trial drug for fatty liver disease improves key markers at 48 weeks
Stock Titan • Dec 19, 2025
Altimmune (ALT) Stock News, Forecasts and Analysis for Dec. 12, 2025: What Investors Are Watching Ahead of Pemvidutide Catalysts
TechStock² • Dec 12, 2025
ALT Stock News: Altimmune, Inc. Stockholder Should Contact Robbins LLP for Information About the Class Action Lawsuit Against Altimmune, Inc.
PR Newswire • Aug 14, 2025
Altimmune stock tumbles after MASH drug trial data
Investing.com • Dec 19, 2025
● Gemini Agentic AI Analyst Insight for ALT
Market Education
- I don't get this Dollar Cost Averaging (DCA). Explain pls Jul 18, 2023
- Trump’s New Tariffs Could Push Up Kitchen Renovation Costs Sep 26, 2025
- I want to day trade, which technical analysis indicators work best. Jul 15, 2023
External Research